Anti-tumor effects of genetic vaccines against HPV major oncogenes

References

• GuanP, Howell-JonesR, LiN, BruniL, de SanjoséS, FranceschiS, CliffordGM. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer2012; 131:2349 - 59; http://dx.doi.org/10.1002/ijc.27485; PMID: 22323075
   PubMed Web of Science ®Google Scholar
• BurchellAN, WinerRL, de SanjoséS, FrancoEL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine2006; 24:Suppl 3S3 - , 52-61; http://dx.doi.org/10.1016/j.vaccine.2006.05.031; PMID: 16950018
   PubMedGoogle Scholar
• zur HausenH. Papillomaviruses and cancer: from basic studies to clinical application. [Review]Nat Rev Cancer2002; 2:342 - 50; http://dx.doi.org/10.1038/nrc798; PMID: 12044010
   PubMed Web of Science ®Google Scholar
• MuñozN, BoschFX, de SanjoséS, HerreroR, CastellsaguéX, ShahKV, SnijdersPJ, MeijerCJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med2003; 348:518 - 27; http://dx.doi.org/10.1056/NEJMoa021641; PMID: 12571259
   PubMed Web of Science ®Google Scholar
• BzhalavaD, GuanP, FranceschiS, DillnerJ, CliffordG. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology2013; 445:224 - 31; http://dx.doi.org/10.1016/j.virol.2013.07.015; PMID: 23928291
   PubMed Web of Science ®Google Scholar
• zur HausenH. Papillomaviruses in the causation of human cancers - a brief historical account. Virology2009; 384:260 - 5; http://dx.doi.org/10.1016/j.virol.2008.11.046; PMID: 19135222
   PubMed Web of Science ®Google Scholar
• GillisonML, KochWM, CaponeRB, SpaffordM, WestraWH, WuL, ZahurakML, DanielRW, ViglioneM, SymerDE, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst2000; 92:709 - 20; http://dx.doi.org/10.1093/jnci/92.9.709; PMID: 10793107
   PubMed Web of Science ®Google Scholar
• HerreroR, CastellsaguéX, PawlitaM, LissowskaJ, KeeF, BalaramP, RajkumarT, SridharH, RoseB, PintosJ, et al, IARC Multicenter Oral Cancer Study Group. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst2003; 95:1772 - 83; http://dx.doi.org/10.1093/jnci/djg107; PMID: 14652239
   PubMed Web of Science ®Google Scholar
• StruykL, van der MeijdenE, MinnaarR, FontaineV, MeijerI, ter ScheggetJ. Transcriptional regulation of human papillomavirus type 16 LCR by different C/EBPbeta isoforms. Mol Carcinog2000; 28:42 - 50; http://dx.doi.org/10.1002/(SICI)1098-2744(200005)28:1<42::AID-MC6>3.0.CO;2-8; PMID: 10820487
   PubMed Web of Science ®Google Scholar
• BarbaresiS, CorteseMS, QuinnJ, AshrafiGH, GrahamSV, CampoMS. Effects of human papillomavirus type 16 E5 deletion mutants on epithelial morphology: functional characterization of each transmembrane domain. J Gen Virol2010; 91:521 - 30; http://dx.doi.org/10.1099/vir.0.016295-0; PMID: 19812262
   PubMed Web of Science ®Google Scholar
• WhiteEA, SowaME, TanMJ, JeudyS, HayesSD, SanthaS, MüngerK, HarperJW, HowleyPM. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci U S A2012; 109:E260 - 7; http://dx.doi.org/10.1073/pnas.1116776109; PMID: 22232672
   PubMed Web of Science ®Google Scholar
• FuB, QuinteroJ, BakerCC. Keratinocyte growth conditions modulate telomerase expression, senescence, and immortalization by human papillomavirus type 16 E6 and E7 oncogenes. Cancer Res2003; 63:7815 - 24; PMID: 14633708
   PubMed Web of Science ®Google Scholar
• KimM-K, KimHS, KimS-H, OhJ-M, HanJY, LimJM, JuhnnYS, SongYS. Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment. Biochem Pharmacol2010; 80:1930 - 5; http://dx.doi.org/10.1016/j.bcp.2010.07.013; PMID: 20643111
   PubMed Web of Science ®Google Scholar
• DiMaioD, MattoonD. Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene2001; 20:7866 - 73; http://dx.doi.org/10.1038/sj.onc.1204915; PMID: 11753669
   PubMed Web of Science ®Google Scholar
• HwangES, NottoliT, DimaioD. The HPV16 E5 protein: expression, detection, and stable complex formation with transmembrane proteins in COS cells. Virology1995; 211:227 - 33; http://dx.doi.org/10.1006/viro.1995.1395; PMID: 7645215
   PubMed Web of Science ®Google Scholar
• StraightSW, HinklePM, JewersRJ, McCanceDJ. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol1993; 67:4521 - 32; PMID: 8392596
   PubMed Web of Science ®Google Scholar
• RodríguezMI, FinbowME, AlonsoA. Binding of human papillomavirus 16 E5 to the 16 kDa subunit c (proteolipid) of the vacuolar H+-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation. Oncogene2000; 19:3727 - 32; http://dx.doi.org/10.1038/sj.onc.1203718; PMID: 10949926
   PubMed Web of Science ®Google Scholar
• AshrafiGH, HaghshenasM, MarchettiB, CampoMS. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer2006; 119:2105 - 12; http://dx.doi.org/10.1002/ijc.22089; PMID: 16823848
   PubMed Web of Science ®Google Scholar
• VenutiA, PaoliniF, NasirL, CorteggioA, RopertoS, CampoMS, BorzacchielloG. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer2011; 10:140; http://dx.doi.org/10.1186/1476-4598-10-140; PMID: 22078316
   PubMed Web of Science ®Google Scholar
• ChengW-F, HungC-F, ChaiC-Y, HsuK-F, HeL, LingM, WuTC. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest2001; 108:669 - 78; http://dx.doi.org/10.1172/JCI200112346; PMID: 11544272
   PubMed Web of Science ®Google Scholar
• PengS, JiH, TrimbleC, HeL, TsaiY-C, YeatermeyerJ, BoydDA, HungCF, WuTC. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol2004; 78:8468 - 76; http://dx.doi.org/10.1128/JVI.78.16.8468-8476.2004; PMID: 15280455
   PubMed Web of Science ®Google Scholar
• DinizMO, LasaroMO, ErtlHC, FerreiraLCS. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D. Clin Vaccine Immunol2010; 17:1576 - 83; http://dx.doi.org/10.1128/CVI.00264-10; PMID: 20739505
   PubMedGoogle Scholar
• GillDK, BibleJM, BiswasC, KellB, BestJM, PunchardNA, CasonJ. Proliferative T-cell responses to human papillomavirus type 16 E5 are decreased amongst women with high-grade neoplasia. J Gen Virol1998; 79:1971 - 6; PMID: 9714245
   PubMed Web of Science ®Google Scholar
• LiuDW, TsaoYP, HsiehCH, HsiehJT, KungJT, ChiangCL, HuangSJ, ChenSL. Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J Virol2000; 74:9083 - 9; http://dx.doi.org/10.1128/JVI.74.19.9083-9089.2000; PMID: 10982354
   PubMed Web of Science ®Google Scholar
• KanodiaS, Da SilvaDM, KastWM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer2008; 122:247 - 59; http://dx.doi.org/10.1002/ijc.23252; PMID: 17973257
   PubMed Web of Science ®Google Scholar
• FeltkampMC, SmitsHL, VierboomMP, MinnaarRP, de JonghBM, DrijfhoutJW, ter ScheggetJ, MeliefCJ, KastWM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol1993; 23:2242 - 9; http://dx.doi.org/10.1002/eji.1830230929; PMID: 7690326
   PubMed Web of Science ®Google Scholar
• MassaS, SimeoneP, MullerA, BenvenutoE, VenutiA, FranconiR. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther2008; 19:354 - 64; http://dx.doi.org/10.1089/hum.2007.122; PMID: 18439124
   PubMed Web of Science ®Google Scholar
• MassaS, PaoliniF, SpanòL, FranconiR, VenutiA. Mutants of plant genes for developing cancer vaccines. Hum Vaccin2011; 7:Suppl147 - 55; http://dx.doi.org/10.4161/hv.7.0.14577; PMID: 21266841
   PubMed Web of Science ®Google Scholar
• LiuD-W, YangY-C, LinH-F, LinM-F, ChengY-W, ChuC-C, TsaoYP, ChenSL. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients. J Virol2007; 81:2869 - 79; http://dx.doi.org/10.1128/JVI.02256-06; PMID: 17202211
   PubMed Web of Science ®Google Scholar
• ChenY-F, LinC-W, TsaoY-P, ChenS-L. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J Virol2004; 78:1333 - 43; http://dx.doi.org/10.1128/JVI.78.3.1333-1343.2004; PMID: 14722288
   PubMed Web of Science ®Google Scholar
• SmahelM, SímaP, LudvíkováV, VonkaV. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology2001; 281:231 - 8; http://dx.doi.org/10.1006/viro.2000.0794; PMID: 11277695
   PubMed Web of Science ®Google Scholar
• SmahelM, SímaP, LudvíkováV, MarinovI, PokornáD, VonkaV. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine2003; 21:1125 - 36; http://dx.doi.org/10.1016/S0264-410X(02)00519-4; PMID: 12559790
   PubMed Web of Science ®Google Scholar
• MassaS, FranconiR, BrandiR, MullerA, MettV, YusibovV, VenutiA. Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine2007; 25:3018 - 21; http://dx.doi.org/10.1016/j.vaccine.2007.01.018; PMID: 17280752
   PubMed Web of Science ®Google Scholar
• VenutiA, MassaS, MettV, VedovaLD, PaoliniF, FranconiR, YusibovV. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine2009; 27:3395 - 7; http://dx.doi.org/10.1016/j.vaccine.2009.01.068; PMID: 19200826
   PubMed Web of Science ®Google Scholar
• DisbrowGL, SunithaI, BakerCC, HanoverJ, SchlegelR. Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology2003; 311:105 - 14; http://dx.doi.org/10.1016/S0042-6822(03)00129-6; PMID: 12832208
   PubMed Web of Science ®Google Scholar
• OetkeC, AuvinenE, PawlitaM, AlonsoA. Human papillomavirus type 16 E5 protein localizes to the Golgi apparatus but does not grossly affect cellular glycosylation. Arch Virol2000; 145:2183 - 91; http://dx.doi.org/10.1007/s007050070048; PMID: 11087100
   PubMed Web of Science ®Google Scholar
• WetherillLF, HolmesKK, VerowM, MüllerM, HowellG, HarrisM, FishwickC, StonehouseN, FosterR, BlairGE, et al. High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors. J Virol2012; 86:5341 - 51; http://dx.doi.org/10.1128/JVI.06243-11; PMID: 22357280
   PubMed Web of Science ®Google Scholar
• YangDH, WildemanAG, SharomFJ. Overexpression, purification, and structural analysis of the hydrophobic E5 protein from human papillomavirus type 16. Protein Expr Purif2003; 30:1 - 10; http://dx.doi.org/10.1016/S1046-5928(03)00049-4; PMID: 12821315
   PubMed Web of Science ®Google Scholar
• LeeSY, HuangZ, KangTH, SoongR-S, KnoffJ, AxenfeldE, WangC, AlvarezRD, ChenCS, HungCF, et al. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. J Mol Med (Berl)2013; 91:1221 - 31; http://dx.doi.org/10.1007/s00109-013-1054-9; PMID: 23715898
   PubMed Web of Science ®Google Scholar
• LinK, RoosinovichE, MaB, HungCF, WuTC. Therapeutic HPV DNA vaccines. Immunol Res2010; 47:86 - 112; http://dx.doi.org/10.1007/s12026-009-8141-6; PMID: 20066511
   PubMed Web of Science ®Google Scholar
• ViciP, MarianiL, PizzutiL, SergiD, Di LauroL, VizzaE, TomaoF, TomaoS, CavallottiC, PaoliniF, et al. Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res2014; 33:29; http://dx.doi.org/10.1186/1756-9966-33-29; PMID: 24667138
   PubMed Web of Science ®Google Scholar
• RistrianiT, FournaneS, OrfanoudakisG, TravéG, MassonM. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells. Oncogene2009; 28:762 - 72; http://dx.doi.org/10.1038/onc.2008.422; PMID: 19015633
   PubMed Web of Science ®Google Scholar
• RamosCR, AbreuPA, NascimentoAL, HoPL. A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide. Braz J Med Biol Res2004; 37:1103 - 9; http://dx.doi.org/10.1590/S0100-879X2004000800001; PMID: 15273812
   PubMed Web of Science ®Google Scholar
• MiyahiraY, MurataK, RodriguezD, RodriguezJR, EstebanM, RodriguesMM, ZavalaF. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods1995; 181:45 - 54; http://dx.doi.org/10.1016/0022-1759(94)00327-S; PMID: 7537312
   PubMed Web of Science ®Google Scholar
• SeoSH, JinHT, ParkSH, YounJI, SungYC. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine2009; 27:5906 - 12; http://dx.doi.org/10.1016/j.vaccine.2009.07.033; PMID: 19651174
   PubMed Web of Science ®Google Scholar